3-环己基-1-溴丙烷 | 34094-21-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机溴化物
• 中文名称: 3-环己基-1-溴丙烷
• 英文名称: (3-bromopropyl)cyclohexane
• 英文别名: 3-cyclohexylpropyl bromide；3-cyclohexyl-1-propylbromide；3-bromopropylcyclohexane
• CAS: 34094-21-8
• 化学式: C₉H₁₇Br
• 分子量: 205.138
• InChiKey: SAJKBMWWUCUTBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

安全信息

• 海关编码：
  2903890090

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 3-Cyclohexylpropyl bromide
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 34094-21-8
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Eye irritation (Category 2), H319
Acute aquatic toxicity (Category 1), H400
Chronic aquatic toxicity (Category 1), H410
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn, N Harmful, Dangerous for the R22, R50/53
environment
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H319 Causes serious eye irritation.
H410 Very toxic to aquatic life with long lasting effects.
Precautionary statement(s)
P273 Avoid release to the environment.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P501 Dispose of contents/ container to an approved waste disposal plant.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C9H17Br
Molecular Weight : 205,14 g/mol
CAS-No. : 34094-21-8
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
3-Cyclohexylpropyl bromide
Acute Tox. 3; Aquatic Acute 1; -
Aquatic Chronic 1; H301,
H410
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
3-Cyclohexylpropyl bromide
Xn, N, R22 - R50/53 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen bromide gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Normal measures for preventive fire protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 4,568
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
Very toxic to aquatic life.

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2810 IMDG: 2810 IATA: 2810
UN proper shipping name
ADR/RID: TOXIC LIQUID, ORGANIC, N.O.S. (3-Cyclohexylpropyl bromide)
IMDG: TOXIC LIQUID, ORGANIC, N.O.S. (3-Cyclohexylpropyl bromide)
IATA: Toxic liquid, organic, n.o.s. (3-Cyclohexylpropyl bromide)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: yes IMDG Marine pollutant: yes IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-环己基-1-溴丙烷 在 三氟乙酸 作用下， 以 二甲基亚砜 为溶剂， 生成 5-(3-Cyclohexylpropyl)-1,3,4-thiadiazol-2-amine
  参考文献：
  名称：

  [1,3,4]噻二唑[3,2-a] -1,2,3-三唑并[4,5-d]嘧啶-9（3H）-one衍生物的合成及抗过敏活性。二。6-烷基和6-环烷基烷基衍生物。

  摘要：

  一系列的6-烷基或6-（环烷基烷基）-[1,3,4]噻二唑[3,2-a] -1,2,3-三唑[4,5-d]嘧啶-9（3H） -由相应的1,3,4-噻二唑-5-胺3b-o合成1b-o，并评估产物的抗过敏活性。在化合物6-（2-环己基乙基）-[1,3,4]噻二唑[3,2-a] -1,2,3-三唑并[4,5-d]嘧啶-9（3H）-1h中发现其X射线晶体学立体结构是一种有前途的新型抗过敏药，具有低毒性和双重活性，可作为白三烯D4受体拮抗剂和口服活性肥大细胞稳定剂。

  DOI：

  10.1248/cpb.40.2391
• 作为产物：
  描述：

  3-环已基-1-丙醇 在 三溴化磷 作用下， 以100%的产率得到3-环己基-1-溴丙烷
  参考文献：
  名称：

  Ouroborand：具有协调驱动开关装置的空腔

  摘要：

  分子开关：ouroborand 协调其腔内的内部侧链，就像它吞下自己的尾巴一样。溶液中锌 (II) 的存在或不存在将腔体在打开和关闭状态之间切换到外部客体（参见方案：深蓝色球体：Zn）。

  DOI：

  10.1002/anie.200906753

文献信息

• 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC) 충남대학교산학협력단(220040084104) BRN ▼314-82-09264

  公开号：KR20160108281A

  公开（公告）日：2016-09-19

  본 발명은 강심 활성을 지니는 화합물 및 이를 함유하는 약학적 조성물을 개시하며, 본 발명에 따른 화합물을 포함하는 조성물은 심부전의 예방 및 치료에 유용하다.

  本发明揭示了具有强心活性的化合物及含有该化合物的药学组合物，根据本发明含有该化合物的组合物对预防和治疗心力衰竭是有益的。
• Synthesis and structure-activity relationship studies of a series of 5-aryl-4,6-dithianonanedioic acids and related compounds: a novel class of leukotriene antagonists
  作者：Carl D. Perchonock、Irene Uzinskas、Mary E. McCarthy、Karl F. Erhard、John G. Gleason、Martin A. Wasserman、Roseanna M. Muccitelli、Jeris F. DeVan、Stephanie S. Tucker

  DOI：10.1021/jm00158a021

  日期：1986.8

  especially good activity. Conformational restriction of either the polar region or lipid tail produced compounds devoid of activity. A number of selected analogues were also evaluated in vivo as antagonists of LTD4-induced bronchoconstriction in the guinea pig. The data established these compounds as a novel class of leukotriene antagonists with potential utility for the treatment of asthma and other immediate

  已经制备了一系列5-炔基-和5-芳基-4,6-二硫代癸二酸和相关化合物以评估白三烯拮抗剂活性。炔基化合物是通过相应的炔属缩醛通过硫缩醛交换制备的。芳基衍生物是由适当的苯甲醛合成的，其中大多数是通过以下三种通用途径之一制备的：迈耶的恶唑啉法，钯偶联法和羟基苯甲醛烷基化。在体外检查了这些类似物拮抗LTD4诱导的豚鼠气管平滑肌收缩的能力，并与[3H] LTD4竞争豚鼠肺膜上的受体位点。这项研究发现了许多构效关系。脂质尾部和极性区域中的两个亚甲基的最佳链长为10-12个原子（或其等价物）。在芳族系列中，邻位和间位取代的化合物具有可比的活性，而对位衍生物则无活性。芳香环和脂质尾部的取代通常具有良好的耐受性，末端苯基（6）和乙炔（33）类似物的活性特别好。极性区或脂质尾部的构象限制产生了缺乏活性的化合物。在体内也评估了许多选择的类似物作为豚鼠中LTD4诱导的支气管收缩的拮抗剂。数据确定这些化合物为一类
• Synthesis and Biological Studies of Novel 2-Aminoalkylethers as Potential Antiarrhythmic Agents for the Conversion of Atrial Fibrillation
  作者：Bertrand Plouvier、Gregory N. Beatch、Grace L. Jung、Alexander Zolotoy、Tao Sheng、Lilian Clohs、Terrance D. Barrett、David Fedida、Wei Q. Wang、Jeff J. Zhu、Yuzhong Liu、Shlomo Abraham、Leah Lynn、Ying Dong、Richard A. Wall、Michael J. A. Walker

  DOI：10.1021/jm0604528

  日期：2007.6.1

  A series of 2-aminoalkylethers prepared as potential antiarrhythmic agents is described. The present compounds are mixed sodium and potassium ion channel blockers and exhibit antiarrhythmic activity in a rat model of ischemia-induced arrhythmias. Structure-activity studies led to the identification of three compounds 5, 18, and 26, which were selected based on their particular in vivo electrophysiological

  描述了制备为潜在抗心律不齐药的一系列2-氨基烷基醚。本发明的化合物是混合的钠和钾离子通道阻滞剂，并且在缺血引起的心律不齐的大鼠模型中表现出抗心律不齐的活性。结构活性研究导致鉴定了三种化合物5、18和26，这是根据它们的特定体内电生理特性选择的，用于两种犬心房颤动（AF）模型的研究。在这两种模型中，这三种化合物均可转化为AF，但仅化合物26被证明具有口服生物利用度。将外消旋物26拆分为其相应的对映体40和41，然后对这些对映体进行生物学测试，结果导致选择（1S，
• [EN] TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS<br/>[FR] TERTRAHYDROBENZAZEPINES EN TANT QUE LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2005097778A1

  公开（公告）日：2005-10-20

  The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

  本发明涉及具有药理活性的新型苯并哌啶衍生物，其制备方法，含有它们的组合物以及它们在治疗神经和精神疾病中的应用。
• [EN] NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GLUCOSYLCÉRAMIDASE NON LYSOSOMALE ET LEURS UTILISATIONS
  申请人：ALECTOS THERAPEUTICS INC

  公开号：WO2020229968A1

  公开（公告）日：2020-11-19

  The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

  这项发明提供了用于抑制葡萄糖酰胺酶的化合物，这些化合物的前药，以及包括这些化合物或这些化合物的前药的药物组合物。